XML 17 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenue:        
Sale of products, net $ 8,371 $ 6,435 $ 15,177 $ 13,493
Cost of goods sold (exclusive of depreciation shown separately below):        
Products 7,785 6,234 13,944 13,005
Gross profit (loss) 586 201 1,233 488
Operating expenses:        
Sales, general and administrative 6,177 3,501 11,006 6,640
Impairment of intangible assets   146   146
Depreciation 150 157 288 313
Amortization 153 189 303 361
Total operating expenses 7,226 4,954 13,044 9,384
Operating loss (6,640) (4,753) (11,811) (8,896)
Other income (expense):        
Unrealized gain (loss) on investments (176) 312 (140) (133)
Impairment of Panacea investment   (1,062)   (1,062)
Gain on Panacea investment conversion 2,548   2,548  
Realized gain (loss) on short-term investment securities   3    
Interest income, net 108 462 220 1,074
Interest expense (14) (19) (21) (31)
Total other income (expense) 2,466 (304) 2,607 (152)
Loss before income taxes (4,174) (5,057) (9,204) (9,048)
Income taxes       38
Net loss (4,174) (5,057) (9,204) (9,086)
Other comprehensive income (loss):        
Unrealized gain (loss) on short-term investment securities (41) 241 (73) 45
Reclassification of (gain) loss to net loss   (3)    
Other comprehensive income (loss) (41) 238 (73) 45
Comprehensive loss $ (4,215) $ (4,819) $ (9,277) $ (9,041)
Net loss per common share - basic and diluted $ (0.03) $ (0.04) $ (0.06) $ (0.07)
Weighted average common shares outstanding - basic and diluted (in thousands) 154,811 138,854 149,564 138,732
Products Other Than Modified Risk Tobacco Products [Member]        
Operating expenses:        
Research and development $ 744 $ 957 $ 1,433 $ 1,770
Modified Risk Tobacco Product [Member]        
Operating expenses:        
Research and development $ 2 $ 4 $ 14 $ 154